+44 20 8123 2220
info@marketpublishers.com

Phosphoglucomutase (PGM 1) Deficiency- Pipeline Insight, 2019

https://marketpublishers.com/r/P112AA61611EN.html
Date: August 2019
Pages: 60
Price: US$ 1,250.00 (Single User License)
ID: P112AA61611EN

Abstracts

This report can be delivered to the clients within 24 Hours

"Phosphoglucomutase (PGM 1) Deficiency- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Phosphoglucomutase (PGM 1) Deficiencypipeline landscape is provided which includes the disease overview and Phosphoglucomutase (PGM 1) Deficiencytreatment guidelines. The assessment part of the report embraces, in depth Phosphoglucomutase (PGM 1) Deficiencycommercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Phosphoglucomutase (PGM 1) Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Phosphoglucomutase (PGM 1) DeficiencyUnderstanding

Congenital disorders of glycosylation (CDGs) are a group of genetic metabolic diseases that are caused by defects in protein glycosylation. Phosphoglucomutase-1 deficiency (PGM1-CDG) is a special CDG that offers new insights into the highly complex relationship among protein glycosylation, other metabolic pathways, and organ system development, according to Sunnie Yan et al (2016). PGM1 Deficiency is caused by loss of function mutations in the PGM1 gene encoding an enzyme responsible for the interconversion of glucose-6-phosphate to glucose-1-phosphate. Glucose-1-phosphate can be utilized to supply UDP-galactose, a substrate that donates galactose subunits for glycoprotein synthesis. The phenotype of PGM1-CDG comprises a wide range of

+44 20 8123 2220
info@marketpublishers.com

clinical manifestations, including hypoglycemia, congenital malformations, early-onset dilated cardiomyopathy, growth retardation, hormonal deficiencies, hepatopathy, hemostatic anomalies, and myopathy.

Phosphoglucomutase (PGM 1) DeficiencyPipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Phosphoglucomutase (PGM 1) Deficiencytargeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Phosphoglucomutase (PGM 1) Deficiencypipeline report covers only one company. Some of the key players include Cerecor Inc. (CERC-801) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Phosphoglucomutase (PGM 1) DeficiencyAnalytical Perspective by DelveInsight

In-depth Phosphoglucomutase (PGM 1) Deficiency Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Phosphoglucomutase (PGM 1) Deficiency Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

+44 20 8123 2220
info@marketpublishers.com

Scope of the report

The Phosphoglucomutase (PGM 1) Deficiencyreport provides an overview of therapeutic pipeline activity for Phosphoglucomutase (PGM 1) Deficiencyacross the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Phosphoglucomutase (PGM 1) Deficiencytherapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Phosphoglucomutase (PGM 1) DeficiencyResearch and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Phosphoglucomutase (PGM 1) Deficiency

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Phosphoglucomutase (PGM 1) Deficiencyto formulate effective R&D strategies

Assess challenges and opportunities that influence Phosphoglucomutase (PGM 1) DeficiencyR&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

+44 20 8123 2220
info@marketpublishers.com

Get in detail information of each product with updated information on each project along with key milestones

Devise Phosphoglucomutase (PGM 1) Deficiencyin licensing and out licensing strategies by identifying prospective partners with progressing projects for Phosphoglucomutase (PGM 1) Deficiencyto enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

5. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY PIPELINE THERAPEUTICS

6. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY-PRODUCTS ANALYSIS

To be continued in the report…….

7. RECENT TECHNOLOGIES

8. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY KEY COMPANIES

9. PHOSPHOGLUCOMUTASE (PGM 1) DEFICIENCY KEY PRODUCTS

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

KEY COMPANIES

Cerecor

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Phosphoglucomutase (PGM 1) Deficiency- Pipeline Insight, 2019
Product link: https://marketpublishers.com/r/P112AA61611EN.html
Price: US$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P112AA61611EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970